Xvivo Perfusion AB 2023 IR
The report highlights XVIVO's financial and operational performance for the fiscal year 2023, achieving record net sales of SEK 597.5 million, representing a 44 percent increase. The company made significant progress in its clinical trials, including the first heart transplant in its US heart preservation trial and completing patient inclusion in the European trial. XVIVO also integrated STAR Teams and Avionord M&P to strengthen its service offerings. Looking ahead, the company plans to focus on scaling up production, launching its heart technology in Europe, and expanding its US organization.
Company: Xvivo Perfusion AB
Sector: Health Care
Country: Sweden
Year: 2023
Type: IR
Pages: 28
Xvivo Perfusion AB
Report On Operations
The report highlights XVIVO's financial and operational performance for the fiscal year 2023, achieving record net sales of SEK 597.5 million, representing a 44 percent increase. The company made significant progress in its clinical trials, including the first heart transplant in its US heart preservation trial and completing patient inclusion in the European trial. XVIVO also integrated STAR Teams and Avionord M&P to strengthen its service offerings. Looking ahead, the company plans to focus on scaling up production, launching its heart technology in Europe, and expanding its US organization.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees